Unichem Laboratories Limited has informed the Exchange regarding Board meeting held on May 22, 2025.

Revenue Growth 20pctPat Growth 25pctResults RestatedExceptional ItemEbitda Margin ExpansionNegative Operating CashflowResults View source PDF Explain this filing

UNICHEMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.0%Reaction day

₹606.04

prior close

₹648.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+3.1% vs market

Pharmaceuticals peers, median of 147sector-0.1%+3.1% vs sector

On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 3.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-2.0

15m

-2.2

30m

-3.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.0-0.1+3.1-0.1+3.1

Next day

+6.4+0.5+5.9-0.3+6.7

+0.3+1.1-0.8-0.0+0.4

-2.0+1.0-3.0+0.2-2.1

+0.4+1.4-1.0+0.0+0.4

-0.1+1.7-1.8+0.5-0.6

-2.1+2.1-4.2-0.2-1.8

15d

+3.2+3.9-0.7+1.4+1.9

-2.6+1.2-3.9-2.8+0.2

+6.0+6.7-0.7+1.4+4.6

-15.7+2.7-18.3-1.0-14.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Unichem Laboratories reported its Q4 and full-year FY25 results, with consolidated revenue from operations growing 18.2% YoY to ₹2,110.97 crores (₹1,785.11 crores in FY24) and standalone revenue up 20.3% to ₹1,735.70 crores. The company swung back to a consolidated profit after tax of ₹137.52 crores from a loss of ₹93.76 crores in FY24, with basic EPS of ₹19.53 versus ₹(13.32). Q4 FY25 consolidated PAT stood at ₹52.97 crores versus a loss of ₹136.74 crores in the year-ago quarter. Statutory auditors N.A. Shah Associates LLP issued an unmodified opinion on both consolidated and standalone results. Comparatives were restated to include the Bayshore Pharmaceuticals (USA) acquisition from Ipca Laboratories. The board also re-appointed cost, secretarial, and internal auditors for FY26.

Likely market impact

Strong financial turnaround and robust revenue growth are positive for shareholders. However, the company reported negative consolidated operating cash flow of ₹137.36 crores in FY25 (vs ₹14 crores inflow last year), driven by higher working capital needs, which warrants attention despite the profit recovery.